×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| STRIDES PHARMA SCIENCE LIMITED | 5003.74 | 133.47 | 4986.16 | 1.45 | 8,120 | 21.6 |
| Aarti Pharmalabs Limited | 3769.06 | 512.21 | 3753.11 | 0 | 8000 | 30.0 |
| MARKSANS PHARMA LTD. | 3217.44 | 480.56 | 3197.34 | 1.06 | 7702 | 22.0 |
STRIDES PHARMA SCIENCE LIMITED, with Security Code 532531, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 475.3 | 540.3 | 520.0 | 617.6 | 554.8 | 554.8 | 610.0 | 550.9 | 556.0 | 498.6 |
| Expenses | 419.8 | 497.0 | 454.4 | 526.8 | 493.7 | 493.7 | 546.9 | 476.8 | 488.0 | 431.4 |
| Operating Profit | 55.6 | 43.3 | 65.7 | 90.8 | 61.0 | 61.0 | 63.0 | 74.1 | 68.0 | 67.2 |
| OPM % | 11.69% | 8.01% | 12.63% | 14.7% | 11% | 11% | 10.33% | 13.45% | 12.23% | 13.48% |
| Other Income | 11.6 | 22.3 | 3.4 | 29.6 | 11.8 | 11.8 | 23.5 | 2.4 | 12.1 | 1.8 |
| Interest | 36.6 | 40.1 | 44.5 | 46.8 | 46.9 | 46.9 | 50.2 | 34.2 | 29.4 | 30.4 |
| Depreciation | 21.5 | 21.3 | 21.1 | 20.8 | 20.3 | 20.3 | 22.0 | 20.9 | 22.4 | 22.1 |
| Profit before tax | 9.1 | 4.2 | 8.8 | 52.9 | 5.7 | 5.7 | 14.4 | 21.4 | 28.4 | 16.4 |
| Tax % | -12.3% | -69.4% | -27.8% | 1.7% | -30.8% | 30.8% | 6.1% | 30.1% | -42.7% | 18.6% |
| Net Profit | 8.0 | 1.3 | 2.5 | 53.7 | 3.9 | 3.9 | 15.3 | 14.9 | 16.1 | 13.3 |
| EPS in Rs | 0.89 | 0.14 | 0.28 | 5.83 | 0.43 | 0.43 | 1.66 | 1.62 | 0 | 1.45 |
| Metrics | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Jun 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 930.0 | 999.4 | 1,037.7 | 1,084.0 | 19.3 | 1,087.5 | 19.3 | 1,201.1 | 1,153.7 | 1,190.4 |
| Expenses | 796.3 | 888.6 | 895.8 | 902.9 | 20.6 | 882.3 | 20.6 | 978.1 | 943.4 | 972.5 |
| Operating Profit | 133.7 | 110.9 | 141.8 | 181.2 | -1.2 | 205.2 | -1.2 | 223.0 | 210.3 | 217.9 |
| OPM % | 14.37% | 11.09% | 13.67% | 16.71% | -6.43% | 18.87% | -6.43% | 18.57% | 18.23% | 18.3% |
| Other Income | 2.7 | -129.1 | -1.3 | -21.6 | 1.0 | 9.0 | 1.0 | 24.5 | 3.2 | -15.4 |
| Interest | 76.4 | 78.6 | 79.3 | 80.2 | 1.5 | 80.4 | 1.5 | 82.1 | 52.2 | 50.3 |
| Depreciation | 59.6 | 60.1 | 51.2 | 49.8 | 0.3 | 48.6 | 0.3 | 50.5 | 48.4 | 48.9 |
| Profit before tax | 6.3 | 8.0 | 20.1 | 37.7 | -2.0 | 88.9 | -2.0 | 118.7 | 115.3 | 130.7 |
| Tax % | -29.1% | -6.5% | -16.3% | -24.6% | 0% | -17.4% | 0% | -16.6% | -21.1% | -20% |
| Net Profit | -9.4 | -149.5 | 54.1 | 10.4 | -2.0 | 68.3 | -2.0 | 93.7 | 90.0 | 85.6 |
| EPS in Rs | -0.79 | -14.54 | 5.42 | 1.98 | -1.14 | 7.62 | -1.14 | 10.12 | 9.55 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | -13% |
| 3 Years: | -30% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 30% |
| 3 Years: | 73% |
| 1 Year: | 79% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 14% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | 34% |
| 3 Years: | 52% |
| TTM: | 265% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 30% |
| 3 Years: | 73% |
| 1 Year: | 79% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|